Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: Development of glycan-targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment

Fig. 2

STn-targeted nanoparticles inhibit galectin-3 and ST6GalNAc-I mRNA expression in vitro. mRNA levels of A galectin-3 or B ST6GalNAc-I in MKN45-Mock and MKN45-ST6GalNAc-I cells after treatment with naked dsRNA-galectin-3, dsRNA-ST6GalNAc-I, dsRNA-random or sTn-targeted NP loaded with dsRNA-galectin-3, dsRNA-ST6GalNAc-I or dsRNA-random for 48 h. Values were normalized to β-actin. Data are the mean ± SEM, n = 3, **p < 0.01 and ***p < 0.001

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us